Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TCP 25

Next Previous
X
Search
Drug Profile

TCP 25

Alternative Names: BioC; BioC gel; TCP-25

Latest Information Update: 05 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lund University
  • Developer Xinnate
  • Class Anti-inflammatories; Antibacterials; Antifungals; Peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epidermolysis bullosa; Varicose ulcer
  • Preclinical Bacterial infections; Mycoses

Most Recent Events

  • 21 Sep 2023 Preclinical trials in Mycoses in Sweden (Transdermal) (Xinnate website, Sep 2023)
  • 07 Dec 2022 Xinnate AB in collaboration with Region Skane completes enrollment in a phase I trial for Epidermolysis bullosa dystrophica (In volunteers) in Sweden (Transdermal)(NCT05378997) (EudraCT2021-004728-14)
  • 19 Oct 2022 Xinnate receives clinical trial application approval from The Swedish Medical Products Agency (Läkemedelsverket), and the Ethics committee for TCP 25 for Epidermolysis bullosa and Varicose ulcer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top